Effect and prognosis of 131Ⅰ combined operation in the treatment of differentiated thyroid cancer in the elderly
LIN Feng YU Min LUO Wenyi ZHANG Bo SHI Yuhong▲
Department of Nuclear Medicine, the 2nd Affiliated Hospital of Chengdu Medical College Nuclear Industry 416 Hospital, Sichuan Province, Chengdu 610051, China
Abstract:Objective To study the effect and prognosis of 131Iodine (131Ⅰ) combined operation for elderly differentiated thyroid cancer. Methods A total of 82 elderly patients with differentiated thyroid cancer treated in the 2nd Affiliated Hospital of Chengdu Medical College from January 2016 to October 2017 were selected for this study. All patients received total thyroidectomy or near total thyroidectomy, and neck lymph node dissection, and then treated with 131Ⅰ. The therapeutic effect, changes of thyroglobulin and thyroglobulin antibody before and after operation, adverse reactions, recurrence and survival situation were observed. Results Among 82 elderly patients with differentiated thyroid cancer, 53 cases were successfully treated after the first 131Ⅰ treatment, and 19 cases were successfully treated after the second 131Ⅰ treatment, with a total success rate of 87.80%. Six months after operation, the level of thyroglobulin and the positive rate of anti-thyroglobulin antibody were significantly lower than those before treatment, the differences were statistically significant (all P < 0.05). During 131Ⅰ treatment, a few patients had short-term adverse reactions such as throat discomfort, neck swelling, abdominal discomfort, and no serious pulmonary fibrosis, bone marrow suppression, liver and kidney function damage. At the end of follow-up, four cases relapsed and three cases died. Conclusion 131Ⅰ combined with total thyroidectomy or near total thyroidectomy is safe, effective and has a good prognosis in the treatment of differentiated thyroid cancer in the elderly, which is worthy of clinical application.
林枫 余敏 罗文溢 张波 史育红▲. 131Ⅰ联合手术治疗老年分化型甲状腺癌的效果及预后[J]. 中国医药导报, 2021, 18(2): 102-105.
LIN Feng YU Min LUO Wenyi ZHANG Bo SHI Yuhong▲. Effect and prognosis of 131Ⅰ combined operation in the treatment of differentiated thyroid cancer in the elderly. 中国医药导报, 2021, 18(2): 102-105.
[1] 潘伟,莫江萍.老年分化型甲状腺癌术后131I治疗的临床预后及其影响因素分析[J].重庆医学,2016,45(20):2823-2826.
[2] 白金权,李柏文,李景东,等.甲状腺癌的手术方式和影响预后相关因素探讨[J].中国地方病防治杂志,2017,32(9):1000-1001.
[3] 谢逸,郑维.老年分化型甲状腺癌的治疗现状[J].中国医师杂志,2017,19(12):1916-1918.
[4] Okkalides D. The Result of Multiple I-131 Treatments on the Effective Half-Life of Retained Radioactivity in Patients Ablated for Differentiated Thyroid Cancer: Possible Evidence for Thyroid Remnant Function Impairment [J]. Cancer Biother Radiopharm,2016,31(2):58-64.
[5] 张学敏,马丽,陈正福,等.分化型甲状腺癌手术后131I治疗临床应用及疗效评价[J].国际肿瘤学杂志,2016,43(4):319-320.
[6] Gosain R,Alexander JS,Gill A,et al. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly [J]. Curr Oncol Rep,2018,20(10):82.
[7] 中华医学会内分泌学分会,中华医学会外科学分会内分泌学组,中国抗癌协会头颈肿瘤专业委员会,等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华核医学与分子影像杂志,2013,33(2):96-115.
[8] 常伟,韩星敏,刘保平,等.老年甲状腺癌患者手术临床疗效和预后分析[J].中华老年医学杂志,2018,37(10):1115-1117.
[9] 陆汉魁.分化型甲状腺癌术后131Ⅰ治疗的规范化问题[J].中国实用外科杂志,2019,39(3):213-215.
[10] Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:What is new and what has changed [J]. Cancer,2017,123(3):372-381.
[11] 张晶虹,张立军,计嘉军,等.甲状腺全切除术与半切除术治疗甲状腺癌的临床效果分析[J].现代生物医学进展,2017,17(18):77-79.
[12] 刘庆,杨华夏,史方富,等.甲状腺全切术治疗分化型甲状腺癌的疗效观察及临床研究探讨[J].现代生物医学进展,2018,18(18):186-189.
[13] Wang TS,Sosa JA. Thyroid surgery for differentiated thyroid cancer-recent advances and future directions [J]. Nat Rev Endocrinol,2018,14(11):670-683.
[14] 刘国军,黄绪群.颈淋巴结择区清除联合131Ⅰ治疗cN0甲状腺癌临床效果分析[J].中国现代普通外科进展,2018,21(7):534-538.
[15] 简闯,史炼钢.精准外科理念下分化型甲状腺癌的手术治疗进展[J].大连医科大学学报,2017,39(2):197-201.
[16] 殷锴,陈洁,丁正强.甲状腺全切术联合放射性碘治疗分化型甲状腺癌的临床效果及预后[J].安徽医学,2019, 40(6):635-638.
[17] 江晶晶,王建华,朱桂祥,等.老年甲状腺癌外科治疗体会[J].实用老年医学,2018,32(3):275-277.
[18] 林岩松.分化型甲状腺癌的碘-131治疗现状和进展[J].中华耳鼻咽喉头颈外科杂志,2019,54(1):62-68.
[19] 夏俊勇,程义壮,刘学公,等.分化型甲状腺癌术后131I清除残余甲状腺组织的疗效及其影响因素分析[J].安徽医学,2016,37(8):944-947.
[20] 冯志平,邓智勇,宋元华,等.131I治疗术后分化型甲状腺癌的疗效及其影响因素[J].昆明医科大学学报,2017, 38(4):72-75.
[21] 朱文茹,戴锦朝,柳炳吉,等.甲状腺全切除术联合131Ⅰ治疗甲状腺癌的临床疗效[J].癌症进展,2018,16(9):1174-1177.
[22] Ortega AJ,Vázquez RG,Cuenca JI,et al.(131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease [J]. Rev Esp Med Nucl Imagen Mol,2016,35(1):29-33.
[23] 樊仁红,张春华,殷宇.分化型甲状腺癌术后131I治疗患者血清TPOAb、TGAb水平变化及其与疗效的关系[J].临床和实验医学杂志,2019,18(18):1967-1970.
[24] 孙希刚,赵芳,周振虎.甲状腺球蛋白对甲状腺癌术后碘131治疗预后的预测价值研究[J].广西医科大学学报,2019,36(1):73-77.
[25] 董鹏.应用131Ⅰ化疗不同年龄背景下分化型甲状腺癌患者术后治疗疗效及预后评估[J].实用癌症杂志,2019, 34(5):818-820.
[26] Ito S,Iwano S,Kato K,et al. Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer [J]. Ann Nucl Med,2018,32(6):418-424.
[27] 常伟,韩星敏,卫琴静,等.手术切除联合131Ⅰ治疗老年分化型甲状腺癌的疗效评价[J].中华老年医学杂志,2020,39(6):684-688.